臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
臺大學術典藏 |
2022-02-21T02:04:31Z |
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
|
Lau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M. |
臺大學術典藏 |
2021-09-01T01:54:13Z |
Liver cancer working group report
|
Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. |
臺大學術典藏 |
2021-09-01T01:54:04Z |
Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia
|
Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG |
臺大學術典藏 |
2021-09-01T01:53:51Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG |
臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
臺大學術典藏 |
2021-09-01T01:53:42Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
ANN-LII CHENG; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
臺大學術典藏 |
2021-08-31T06:29:27Z |
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
|
Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. |
臺大學術典藏 |
2021-08-31T06:29:16Z |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
|
Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K. |
臺大學術典藏 |
2021-08-31T06:29:14Z |
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|
Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A. |
臺大學術典藏 |
2021-08-31T06:29:14Z |
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K. |
臺大學術典藏 |
2021-08-31T06:29:13Z |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
|
Ryoo B.-Y.; ANN-LII CHENG; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. |
臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
臺大學術典藏 |
2021-07-03T03:34:19Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Cheng A.-L. |
臺大學術典藏 |
2021-07-03T03:34:14Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
Cheng A.L.; Amarapurkar D.; Chao Y.; PEI-JER CHEN; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
臺大學術典藏 |
2021-07-03T03:33:58Z |
Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study
|
Park J.-W.; Chen M.; Colombo M.; Roberts L.R.; Schwartz M.; PEI-JER CHEN; Kudo M.; Johnson P.; Wagner S.; Orsini L.S.; Sherman M. |
臺大學術典藏 |
2021-06-25T08:49:25Z |
Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
|
Lee S.U.; Yoon S.M.; Cheng J.C.-H.; Kim T.H.; Kim B.H.; Park J.-H.; Jung J.; Tsai C.-L.; YUN CHIANG; Park J.-W. |
臺大學術典藏 |
2021-05-21T07:17:41Z |
Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
|
Lee S.U.; Yoon S.M.; Cheng J.C.-H.; Kim T.H.; Kim B.H.; Park J.-H.; Jung J.; CHIAO-LING TSAI; Chiang Y.; Park J.-W. |
國立成功大學 |
2021 |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
|
Ryoo, B.-Y.;Cheng, A.-L.;Ren, Z.;Kim, T.-Y.;Pan, H.;Rau, K.-M.;Choi, H.J.;Park, J.-W.;Kim, J.H.;Yen, C.J.;Lim, H.Y.;Zhou, D.;Straub, J.;Scheele, J.;Berghoff, K.;Qin, S. |
臺大學術典藏 |
2020-08-11T08:36:43Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.;Cheng A.-L.;Park J.-W.;Park J.H.;Po-Chin Liang;Hidaka H.;Izumi N.;Heo J.;Lee Y.J.;Sheen I.-S.;Chiu C.-F.;Arioka H.;Morita S.;Arai Y.; Kudo M.; Cheng A.-L.; Park J.-W.; Park J.H.; PO-CHIN LIANG; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |